Clinical Endpoints: An SMO Connecting Patient’s to Hope

At Clinical Endpoints, we are a Site Management Organization (SMO) that is dedicated to revolutionizing neurology research to enhance the lives of individuals with neurological disorders. Our focus spans various conditions, including Alzheimer’s and Parkinson’s disease, as we seek innovative treatments and therapies that can transform patient outcomes.

Alzheimer’s disease remains one of the most urgent challenges in neurology, affecting millions globally. This condition not only impacts those diagnosed but also their families and caregivers, emphasizing the need for comprehensive research. The current landscape highlights a growing emphasis on novel therapies targeting the underlying mechanisms of the disease, including amyloid plaques and tau proteins.

Clinical Endpoints is at the forefront of Alzheimer’s research, actively leading the industry with groundbreaking clinical trials that explore innovative therapies. Recent developments include targeted approaches to reduce amyloid-beta accumulation and strategies to prevent tau protein tangles, both crucial in addressing cognitive decline. An often-overlooked aspect is the role of neuroinflammation, which we are studying through anti-inflammatory therapies.

“Collaboration is essential in this journey,” says Clinical Endpoints Medical Director Constantine Moschonas, MD, underscoring our partnerships with top institutions and advocacy groups to foster impactful discoveries.

Clinical Endpoints is dedicated to advancing Alzheimer’s and Parkinson’s research while Connecting Patients to Hope – fostering optimism for patients and their families. Join us in this important mission to uncover effective treatments and potential breakthroughs. To arrange a conversation with our research experts.